Glipizide
SIGMA/G117 - solid
Synonym: 1-
CAS Number: 29094-61-9
Empirical Formula (Hill Notation): C21H27N5O4S
Molecular Weight: 445.54
EC Number: 249-427-6
MDL Number: MFCD00072159
Linear Formula: C21H27N5O4S
Product Type: Chemical
| color | white |
| form | solid |
| InChI | 1S/C21H27N5O4S/c1-15-13-2 |
| InChI key | ZJJXGWJIGJFDTL-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | Cc1cnc(cn1)C(=O)NCCc2ccc( |
| solubility | DMSO: 48 mg/mL |
| methanol: 1.9 mg/mL |
| Application: | Glipizide has been used in: • chick embryo yolk sac membrane (YSM) and chorioallantoic membrane (CAM) assay • MCF-7 breast cancer assay on chorioallantoic membrane (CAM) • metastasis assays • rat aortic ring assay • in vivo matrigel plug assay • 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay • flow cytometry • western blotting |
| Biochem/physiol Actions: | Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) plays a vital role in potassium balance. It is an ATP-dependent K+ channel blocker. The encoded protein is liable for the elimination of potassium in exchange for the absorption of sodium by the epithelial sodium channel (ENaC). Mutation in KCNJ1 is linked with several diseases, such as, antenatal Bartter syndrome and diabetes. Glipizide helps to repress the development of tumors and metastasis by preventing angiogenesis. |
| General description: | Potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) codes for a renal outer medullary potassium channel (ROMK1, Kir1.1). Glipizide is an antidiabetic drug, that is used to treat type II diabetes.(5) |
| Packaging: | 1 g in poly bottle |
| Packaging: | 500 mg in poly bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| UNSPSC | 12352200 |

